Clinical remission in juvenile idiopathic arthritis after termination of etanercept
Open Access
- 21 July 2012
- journal article
- research article
- Published by Springer Nature in Rheumatology International
- Vol. 33 (10) , 2657-2660
Abstract
Biologicals are very effective for inhibiting disease progression in active juvenile idiopathic arthritis (JIA). To date, there have been no recommendations on how and when to stop therapy with TNF inhibitors. Our objective was to analyze characteristics and the disease course of JIA patients who discontinued etanercept due to achievement of inactive disease. Data of 39 patients with JIA from two clinical pediatric rheumatology centers in Bydgoszcz and Lublin (Poland) were analyzed retrospectively. All patients discontinued etanercept due to a remission on treatment. Etanercept was started after a mean 33.7 ± 36 (range 3–137) months of disease. The mean duration of therapy with etanercept was 34.7 ± 16.7 (range 6–72) months, with a mean duration of remission on medication 21.3 ± 9.6 (range 4–42) months before withdrawal of etanercept. The mean duration of remission after etanercept discontinuation was 14.2 ± 12.1 (range of 1–60) months. Only 12/39 (30.8 %) patients did not develop a disease exacerbation until the end of the study. Early flares, that is less than 6 months after termination of etanercept, were observed in 15/39 (38.5 %) patients. Twelve (30.8 %) patients restarted etanercept after exacerbation—all patients responded satisfactorily. Our data show that etanercept discontinuation in a substantial proportion of JIA patients results in early disease exacerbation. In many cases, reintroduction of etanercept is needed. Patients, in whom etanercept was restarted, responded satisfactorily.Keywords
This publication has 8 references indexed in Scilit:
- A follow-up study of patients with juvenile idiopathic arthritis who discontinued etanercept due to disease remission.2011
- Duration of etanercept treatment and reasons for discontinuation in a cohort of juvenile idiopathic arthritis patientsRheumatology, 2010
- Discontinuation of Etanercept After Successful Treatment in Patients with Juvenile Idiopathic Arthritis: Figure 1.The Journal of Rheumatology, 2010
- When and how to stop etanercept after successful treatment of patients with juvenile idiopathic arthritisAnnals of the Rheumatic Diseases, 2009
- Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis.2004
- Toward an understanding of the long-term outcome of juvenile idiopathic arthritis.2004
- Long-term outcomes and predictors of outcomes for patients with juvenile idiopathic arthritisBest Practice & Research Clinical Rheumatology, 2002
- Long-term outcomes and predictors of outcomes for patients with juvenile idiopathic arthritisBest Practice & Research Clinical Rheumatology, 2002